REGENXBIO reports Q4 net loss $62.9M, cash $314M; pipeline milestones for 2024

REGENXBIO Inc.

2023-FY EPS reported -$6.02 revenue$90,242,000

Q4 net loss $62.9M ($1.43/sh); full year net loss $263.5M ($6.02/sh); 2023 revenue $90.2M vs $112.7M in 2022.
Cash, cash equivalents and marketable securities $314.1M as of Dec 31, 2023; expected to fund operations into H2 2025.
ABBV-RGX-314 wet AMD subretinal pivotal trials on track for global submissions late 2025-early 2026; suprachoroidal data mid-2024.
RGX-202 Duchenne pivotal dose determination mid-2024; RGX-121 MPS II BLA filing planned for 2024 via accelerated approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.